HTG to Collaborate With OmiCure, Providing Transcriptomic Data Across Several Cancer Indications
TUCSON, Ariz. and PARIS, Oct. 26, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science...
Diagnostics
LifeMD, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 10, 2022
NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a rapidly growing direct-to-patient telehealth company, today announced...
Plus Therapeutics Announces Selection of “Rhenium (186Re) Obisbemeda” as International Non-Proprietary Name for 186RNL
AUSTIN, Texas, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
Shineco, Inc. to Acquire Controlling Equity Interest in Changzhou Biowin Pharmaceutical Co., Ltd to Step into Point-of-Care Testing Industry
BEIJING, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc.(“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese...
SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022
Cumulative interim analysis of outcomes by fungal disease type highlighted in a platform presentation demonstrates 82.3% positive clinical outcomes in...
Press release Biocartis Group NV: Biocartis Reports Results of Third Quarter of 2022
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA...
Codexis to Report Third Quarter 2022 Financial Results on November 3
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the...
Chembio Diagnostics to Report Third Quarter 2022 Financial Results on November 3, 2022
HAUPPAUGE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on...
Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
Awarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186RNL...
Predictive Oncology Announces New Chief Executive Officer Raymond F. Vennare to Lead Company Growth
CEO and CHairman of the Board Raymond F. VennareEAGAN, Minn., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) is...
Nanomix Enters into Distribution Agreement for the eLab System with Diaclinic SpA in Chile
SAN LEANDRO, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development...
CytoDyn Announces Appointment of Additional Directors with Industry Experience
Stephen Simes career public biotech company CEO and Ryan Dunlap CFO with public biotech company experience join Board VANCOUVER, Wash.,...
Enzo Biochem, Inc. Appoints Patricia Eckert, CPA as Interim CFO
- David Bench resigning to pursue a new career opportunity -NEW YORK, NY, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Enzo...
HMNC Brain Health Raises EUR 14.3 million to Advance Precision Psychiatry Therapies
Round Comprised of New and Former Investors, Including Dr. Josef Ackermann, Wilhelm Beier, Toni Kroos, and Carsten Maschmeyer First of...
Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute
Figure: 1 Compound F3 and enhanced activity derivative F3-8-60 directly bind to K-RAS Figure: 2 F3 class compounds block RAS...
Maravai LifeSciences Temporarily Reinstates Carl Hull as CEO Amidst Pending Noncompetition Litigation
Maravai LifeSciences and Recently-Appointed CEO Trey Martin Vigorously Defending Against SuitSAN DIEGO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Executive...
ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors
Exclusive license from Helmholtz Munich will enable ITM to access IP and know-how to develop and commercialize ITM-31 for glioblastoma...
AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
Enrollment Ongoing in Phase 2/3 Pivotal Trial of Epetraborole in Treatment- Refractory MAC Lung DiseaseMENLO PARK, Calif., Oct. 19, 2022...
VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388
– Study reveals the structural basis of receptor activation and signaling by IL-27 cytokine –– Study elucidates how SRF388 binds to...
Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress
ReSPECT-LM Phase 1 clinical trial selected as TOP Trials Oral Presentation Treatment was well tolerated without dose limiting toxicities and...